# MagnetisMM-7 (NCT05317416)

> Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05317416
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Multiple Myeloma
- Interventions: Elranatamab; Lenalidomide; Lenalidomide; Elranatamab
- Enrollment: 854
- Primary outcome: Progression Free Survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 3
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=magnetismm-7-nct05317416